{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:11:25Z","timestamp":1790820685393,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2008,1,3]],"date-time":"2008-01-03T00:00:00Z","timestamp":1199318400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1007\/s11095-007-9514-y","type":"journal-article","created":{"date-parts":[[2008,1,3]],"date-time":"2008-01-03T00:46:47Z","timestamp":1199321207000},"page":"1521-1530","source":"Crossref","is-referenced-by-count":159,"title":["Solid Lipid Nanoparticles as Delivery Systems for Bromocriptine"],"prefix":"10.1007","volume":"25","author":[{"given":"Elisabetta","family":"Esposito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Fantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Drechsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Paccamiccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Sivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Lain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enea","family":"Menegatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Morari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Cortesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,1,3]]},"reference":[{"key":"9514_CR1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1023\/A:1011042627714","volume":"18","author":"H. Bunjes","year":"2001","unstructured":"H. Bunjes, M. Drechsler, M. H. J. Koch, and K. Westesen. Incorporation of the Model Drug Ubidecarenone into Solid Lipid Nanoparticles. Pharm. Res. 18:287\u2013293 (2001).","journal-title":"Pharm Res."},{"key":"9514_CR2","first-page":"213","volume-title":"Microencapsulation","author":"K. Westesen","year":"1996","unstructured":"K. Westesen and B. Siekmann. Biodegradable colloidal drug carrier systems based on solid lipids. In S. Benita (ed.), Microencapsulation, Marcel Dekker, New York, 1996, pp. 213\u2013258."},{"key":"9514_CR3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0168-3659(97)00046-1","volume":"48","author":"K. Westesen","year":"1997","unstructured":"K. Westesen, H. Bunjes, and M.H.J. Koch. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Rel. 48:223\u201323 (1997).","journal-title":"J. Control Rel."},{"key":"9514_CR4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","volume":"50","author":"R. H. Muller","year":"2000","unstructured":"R.H. Muller, K. Mader, and S. Gohla. Solid lipid nanoparticles (SLN) for controlled delivery-a review of the state of the art. Eur J Pharm Biopharm. 50:161\u2013177 (2000).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"9514_CR5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0169-409X(01)00105-3","volume":"47","author":"W. Mehnert","year":"2001","unstructured":"W. Mehnert, and K. Mader. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 47:165\u2013196 (2001).","journal-title":"Adv. Drug. Deliv Rev."},{"key":"9514_CR6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/02652040010018056","volume":"19","author":"A. Dingler","year":"2002","unstructured":"A. Dingler, and S.H. Gohla. Production of solid lipid nanoparticles (SLN): scaling up feasibilities. J Microencapsul 19:11\u201318 (2002).","journal-title":"J. Microencapsul."},{"key":"9514_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/713817583","volume":"19","author":"V. Jenning","year":"2002","unstructured":"V. Jenning, A. Lippacher, and S.H. Gohla. Medium scale production of solid lipid nanoparticles (SLN) by high pressure homogenisation. J Microencapsul 19:1\u201310 (2002).","journal-title":"J. Microencapsul."},{"key":"9514_CR8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0378-5173(00)00623-2","volume":"214","author":"A. Lippacher","year":"2001","unstructured":"A. Lippacher, R.H. Muller, and K. Mader. Preparation of semisolid drug carriers for topical application based on solid lipid nanoparticles. Int J Pharm. 214:9\u201312 (2001).","journal-title":"Int. J. Pharm."},{"key":"9514_CR9","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.2174\/1381612043384826","volume":"10","author":"A. V. Kabanov","year":"2004","unstructured":"A.V. Kabanov, and E.V. Batrakova. New technologies for drug delivery across the blood brain barrier. Curr. Pharm. Des. 10:1355\u20131363 (2004).","journal-title":"Curr. Pharm. Des."},{"key":"9514_CR10","first-page":"2000","volume":"3","author":"J. Temsamani","year":"2000","unstructured":"J. Temsamani, J. M. Scherrmann, A. R. Rees, and M. Kaczorek. Brain drug delivery technologies: novel approaches for transporting therapeutics. PSTT. 3:2000 (2000).","journal-title":"PSTT."},{"key":"9514_CR11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0165-0173(01)00083-2","volume":"38","author":"E. H. Lo","year":"2001","unstructured":"E.H. Lo, A.B. Singhal, V.P. Torchilin, and N.J. Abbott. Drug delivery to damaged brain. Brain Res Brain Res Rev. 38:140\u2013148 (2001).","journal-title":"Brain Res. Brain Res. Rev."},{"key":"9514_CR12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0169-409X(98)00090-8","volume":"36","author":"N. Bodor","year":"1999","unstructured":"N. Bodor, and P. Buchwald. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Ad. Drug Deliv Rev. 36:229\u2013254 (1999).","journal-title":"Ad. Drug Deliv. Rev."},{"key":"9514_CR13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0169-409X(98)00088-X","volume":"36","author":"T. Terasaki","year":"1999","unstructured":"T. Terasaki, and K. Hosoya. The blood\u2013brain barrier efflux transporters as a detoxifying system for the brain. Adv Drug Deliv Rev. 36:195\u2013209 (1999).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"9514_CR14","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ijpharm.2005.03.031","volume":"298","author":"E. Garcia-Garcia","year":"2005","unstructured":"E. Garcia-Garcia, K. Andrieux, S. Gilb, and P. Couvreur. Colloidal carriers and blood\u2013brain barrier (BBB) translocation: A way to deliver drugs to the brain. Int J Pharm. 298:274\u2013292 (2005).","journal-title":"Int. J. Pharm."},{"key":"9514_CR15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1001\/archneur.1993.00540020018011","volume":"50","author":"A. J. Hughes","year":"1993","unstructured":"A.J. Hughes, S.E. Daniel, S. Blankson, and A.J. Lees. Clinicopathologic study of 100 cases of Parkinson\u2019s disease. Arch Neurol. 50:140\u2013148 (1993).","journal-title":"Arch. Neurol."},{"key":"9514_CR16","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0140-6736(02)08520-3","volume":"359","author":"O. Rascol","year":"2002","unstructured":"O. Rascol, C. Goetz, W. Koller, W. Poewe, and C. Sampaio. Treatment interventions for parkinson\u2019s disease: an evidence based assessment. Lancet. 359:1589\u20131598 (2002).","journal-title":"Lancet."},{"key":"9514_CR17","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1471-1931(00)00031-8","volume":"23","author":"J. A. Obeso","year":"2000","unstructured":"J.A. Obeso, C.W. Olanow, and J.G. Nutt. Levodopa motor complications in Parkinson\u2019s disease. Trends Neurosci. 23:S2\u2013S7 (2000).","journal-title":"Trends Neurosci."},{"key":"9514_CR18","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1460-9568.1994.tb00584.x","volume":"6","author":"J. A. Obeso","year":"1994","unstructured":"J.A. Obeso, F. Grandas, M.T. Herrero, and R. Horowski. The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. Eur J Neurosci. 6:889\u2013897 (1994).","journal-title":"Eur. J. Neurosci."},{"key":"9514_CR19","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.clinthera.2006.08.004","volume":"28","author":"T. Kvermo","year":"2006","unstructured":"T. Kvermo, S. Hartter, and E. Burger. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther. 28:1065\u20131078 (2006).","journal-title":"Clin. Ther."},{"key":"9514_CR20","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/mds.870130207","volume":"13","author":"R. K. B. Pearce","year":"1998","unstructured":"R.K.B. Pearce, T. Banerji, P. Jenner, and C.D. Marsden. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-DOPA in the MPTP-treated marmoset. Mov Disord. 13:234\u2013241 (1998).","journal-title":"Mov. Disord."},{"key":"9514_CR21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0301-0082(96)00040-8","volume":"50","author":"R. K. W. Schwarting","year":"1996","unstructured":"R.K.W. Schwarting, and J.P. Huston. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol. 50:275\u2013331 (1996).","journal-title":"Prog. Neurobiol."},{"key":"9514_CR22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1208\/ps050430","volume":"5","author":"E. Esposito","year":"2003","unstructured":"E. Esposito, N. Eblovi, S. Rasi, M. Drechsler, G. M. Di Gregorio, E. Menegatti, and R. Cortesi. Lipid based supramolecular systems for topical application: a preformulatory study. AAPS PharmSci. 5:4 Article 30 (2003).","journal-title":"AAPS PharmSci."},{"key":"9514_CR23","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1063\/1.1678153","volume":"57","author":"D. E. Koppel","year":"1972","unstructured":"D.E. Koppel. Analysis of macromolecular polydispersity in intensity correlation spectroscopy: The method of cumulants. J. Chem. Phys. 57:4814\u20134820 (1972).","journal-title":"J. Chem. Phys."},{"key":"9514_CR24","unstructured":"http:\/\/en.wikipedia.org\/wiki\/Dynamic_light_scattering ."},{"key":"9514_CR25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1023\/A:1010067107182","volume":"2","author":"R. Pecora","year":"2000","unstructured":"R. Pecora. Dynamic Light Scattering Measurement of Nanometer Particles in Liquids J. Nanoparticle Res. 2:123\u2013131 (2000).","journal-title":"Nanoparticle Res."},{"key":"9514_CR26","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0022-2836(88)90607-9","volume":"204","author":"P. Mariani","year":"1988","unstructured":"P. Mariani, V. Luzzati, and H. Delacroix. Cubic phases of lipid-containing systems. Structure analysis and biological implications. J Mol Biol. 204:165\u2013189 (1988).","journal-title":"J. Mol. Biol."},{"key":"9514_CR27","doi-asserted-by":"crossref","first-page":"9591","DOI":"10.1523\/JNEUROSCI.2546-05.2005","volume":"95","author":"M. Marti","year":"2005","unstructured":"M. Marti, F. Mela, M. Fantin, S. Zucchini, J.M. Brown, J. Witta, M. DiBenedetto, B. Buzas, R.K. Reinscheid, S. Salvadori, R. Guerrini, P. Romualdi, S. Candeletti, M. Simonato, B.M. Cox, and M. Morari. Blockade of nociceptin\/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson\u2019s disease. J Neurosci. 95:9591\u20139601 (2005).","journal-title":"J. Neurosci."},{"key":"9514_CR28","unstructured":"G. Paxinos and C. Watson. The rat brain in stereotaxic coordinates. Ed. Academic, Sydney (1982)."},{"key":"9514_CR29","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0006-8993(70)90187-3","volume":"24","author":"U. Ungerstedt","year":"1970","unstructured":"U. Ungerstedt, and G.W. Arbuthnott. Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res. 24:485\u2013493 (1970).","journal-title":"Brain Res."},{"key":"9514_CR30","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1523\/JNEUROSCI.4346-06.2007","volume":"27","author":"M. Marti","year":"2007","unstructured":"M. Marti, C. Trapella, R. Viaro, and M. Morari. The nociceptin\/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway. J Neurosci. 27:1297\u20131307 (2007).","journal-title":"J. Neurosci."},{"key":"9514_CR31","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1037\/0735-7044.102.5.748","volume":"102","author":"P. R. Sanberg","year":"1988","unstructured":"P.R. Sanberg, M.D. Bunsey, M. Giordano, and A.B. Norman. The catalepsy test: ist ups and downs. Behav Neurosci. 102:748\u2013759 (1988).","journal-title":"Behav. Neurosci."},{"key":"9514_CR32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jconrel.2003.11.012","volume":"95","author":"K. Jores","year":"2004","unstructured":"K. Jores, W. Mehnert, M. Drechsler, H. Bunjes, C. Johann, and K. Maeder. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J. Control. Release. 95:217\u2013227 (2004).","journal-title":"J. Control. Release"},{"key":"9514_CR33","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1023\/A:1018947208597","volume":"16","author":"J. C. Olivier","year":"1999","unstructured":"J.C. Olivier, L. Fenart, R. Chauvet, C. Pariat, R. Cecchelli, and W. Couet. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm Res. 16:1836\u20131842 (1999).","journal-title":"Pharm. Res."},{"key":"9514_CR34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0169-409X(00)00122-8","volume":"47","author":"J. Kreuter","year":"2001","unstructured":"J. Kreuter. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev. 47:65\u201381 (2001).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"9514_CR35","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1021\/js980084y","volume":"87","author":"S. Ulrike","year":"1998","unstructured":"S. Ulrike, S. Petra, U. Sven, and B.A. Sabel. Nanoparticle technology for delivery of drugs across the blood\u2013brain barrier. J Pharm Sci. 87:1305\u20131307 (1998).","journal-title":"J. Pharm. Sci."},{"key":"9514_CR36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jconrel.2003.08.006","volume":"93","author":"R. P. Lockmana","year":"2003","unstructured":"R.P. Lockmana, M.O. Oyewumi, J.M. Koziara, K.E. Roder, R.J. Mumper, and D.D. Allen. Brain uptake of thiamine-coated nanoparticles. J. Control Release. 93:271\u2013282 (2003).","journal-title":"J .Control. Release"},{"key":"9514_CR37","first-page":"461","volume":"36","author":"Z. R. Zhang","year":"2001","unstructured":"Z.R. Zhang, J.X. Wang, and J. Lu. Optimization of the preparation of 30,50-dioctanoyl-5-fluoro-20-deoxyuridine pharmacosomes using central composite design. Acta Pharmaceutica Sinica. 36:461\u2013465 (2001).","journal-title":"Acta Pharmaceutica Sinica."},{"key":"9514_CR38","first-page":"57","volume":"31","author":"Y. X. Peng","year":"2000","unstructured":"Y.X. Peng, Y.L. Zhuang, and G.T. Liao. Study on bone marrow targeting daunorubicin polybutylcyanoacrylate nanoparticles. Chin. J. Pharm. 31:57\u201361 (2000).","journal-title":"Chin. J. Pharm."},{"key":"9514_CR39","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0169-409X(95)00024-2","volume":"16","author":"S. M. Moghimi","year":"1995","unstructured":"S.M. Moghimi. Mechanisms regulating body distribution of nanospheres conditioned with pluronic and tetronic block co-polymers. Adv. Drug Deliv. Rev. 16:183\u2013186 (1995).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"9514_CR40","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1046\/j.1460-9568.2002.01967.x","volume":"15","author":"P. Calvo","year":"2002","unstructured":"P. Calvo, B. Gouritin, H. Villarroya, F. Eclancher, C. Giannavola, C. Klein, J.P. Andreux, and P. Couvreur. Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur. J. Neurosci. 15:1317\u20131326 (2002).","journal-title":"Eur. J. Neurosci."},{"key":"9514_CR41","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1124\/jpet.102.039669","volume":"303","author":"I. Brigger","year":"2002","unstructured":"I. Brigger, J. Morizet, G. Aubert, H. Chacun, M.J. Terrier-Lacombe, P. Couvreur, and G. Vassal. Poly(ethylene glycol)- coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J. Pharmacol Exp. Ther. 303:928\u2013936 (2002).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"9514_CR42","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1023\/A:1012098005098","volume":"14","author":"J. Kreuter","year":"1997","unstructured":"J. Kreuter. Delivery of loperamide across the blood-brain barrier with Polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm. Res. 14:325\u2013328 (1997).","journal-title":"Pharm. Res."},{"key":"9514_CR43","first-page":"1772","volume":"20","author":"J. M. Koziara","year":"2003","unstructured":"J.M. Koziara, P.R. Lockman, D.D. Allen, and R.J. Mumper. In situ blood-brain barrier transport of nanoparticles. Pharm. Res. 20:1772\u20131778 (2003).","journal-title":"Res."},{"key":"9514_CR44","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0168-3659(99)00007-3","volume":"59","author":"S. C. Yang","year":"1999","unstructured":"S.C. Yang, L.F. Lu, Y. Cai, J.B. Zhu, B.W. Liang, and C.Z. Yang. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control Release. 59:299\u2013307 (1999).","journal-title":"J. Control Release"},{"key":"9514_CR45","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2174\/156720106776359230","volume":"3","author":"S. B. Tiwari","year":"2006","unstructured":"S.B. Tiwari, and M.M. Amiji. A Review of Nanocarrier-Based CNS Delivery Systems. Current Drug Delivery. 3:219\u2013232 (2006).","journal-title":"Current Drug Delivery"},{"key":"9514_CR46","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.expneurol.2005.06.006","volume":"197","author":"E. L. Lane","year":"2006","unstructured":"E.L. Lane, S.C. Cheetam, and P. Jenner. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease. Exp. Neurol. 197:284\u2013290 (2006).","journal-title":"Exp. Neurol."}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-007-9514-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-007-9514-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-007-9514-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T05:43:03Z","timestamp":1559367783000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-007-9514-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,3]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["9514"],"URL":"https:\/\/doi.org\/10.1007\/s11095-007-9514-y","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,3]]}}}